Skip to content
drillr.ai
Sign up

301520.SZ

万邦医药

SZSE · M 科研服务 · CN

CNY 77.10
+8.36%
Ask drillr

  • Aug 28, 2026, 10:18 UTC

    Wanbang Pharmaceutical announced its H1 2026 results: revenue of 87.7577 million yuan, down 40.24% year-on-year; net profit attributable to shareholders of 138,000 yuan, down 99.49% year-on-year; non-recurring net loss of 13.4309 million yuan, turning from profit to loss.

    Source:

  • Jul 17, 2026, 12:11 UTC

    Shenzhen Stock Exchange took self-regulatory measures against 173 abnormal securities trading behaviors from July 13 to July 17, 2026, including intraday price manipulation and false orders, and conducted key monitoring on Wanbang Pharmaceutical for severe abnormal stock price fluctuations.